Immunotherapy Drugs Market, By Therapy Type (Immune checkpoint inhibitors, Monoclonal antibodies, Vaccines, Adoptive Cell Therapies, Immune System Modulators, Oncolytic Virus Therapy), By Route of Administration (Intravenous, Oral, Intramuscular, Subcutaneous, Others), By Indication (Cancer, Autoimmune Diseases, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Feb 2025

Code : CMI525

Pages :150

Formats :

Excel and PDF

Industry : Biotechnology

Immunotherapy Drugs Market Size and Trends

Global immunotherapy drugs market is estimated to be valued at USD 185.72 Bn in 2025 and is expected to reach USD 398.16 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 11.5% from 2025 to 2032.

Immunotherapy Drugs Market Key Factors

To learn more about this report, Request sample copy

The immunotherapy drugs market is witnessing positive growth trends over the years. Immune checkpoint inhibitors, which help unleash the body's own immune response against cancer, have emerged as a major category of immunotherapy. Checkpoint inhibitor drugs such as Keytruda, Opdivo and Tecentriq are widely adopted drugs. Rising incidence of cancer cases globally and increasing preference for precision medicines are key factors boosting demand for immunotherapy drugs over the forecast period.

Rising awareness about cancer immunotherapy

With increasing incidence of various types of cancer worldwide, there is rising awareness among public as well as medical professionals about innovative treatment options. Cancer immunotherapy is gaining prominence as it utilizes body's own immune system to fight cancer in a novel way. Various advocacy groups are educating people about this option through awareness campaigns. These are highlighting how immunotherapy helps activate patient's own T cells to identify and destroy cancer cells in a targeted manner. This avoids non-specific killing of normal cells like other treatment options. The success stories showcased by advocacy groups and patients who benefited from immunotherapy are helping change perceptions. Where earlier surgery or chemo was the default option, now patients ask doctors about immunotherapy upfront. Medical conferences are dedicating special sessions to share research advances and real-world experiences with immunotherapy.